PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,345,350 | -20.4% | 956,377 | +4.0% | 0.00% | -25.0% |
| Q2 2023 | $36,848,425 | +2.3% | 919,601 | +4.2% | 0.00% | -20.0% |
| Q1 2023 | $36,026,429 | +110173.7% | 882,784 | +4.3% | 0.01% | 0.0% |
| Q4 2022 | $32,670 | -99.9% | 846,163 | +3.3% | 0.01% | -28.6% |
| Q3 2022 | $43,580,000 | -6.2% | 819,330 | +2.8% | 0.01% | 0.0% |
| Q2 2022 | $46,474,000 | -23.0% | 797,153 | +0.8% | 0.01% | -12.5% |
| Q1 2022 | $60,354,000 | +19.8% | 790,812 | -5.5% | 0.01% | +33.3% |
| Q4 2021 | $50,370,000 | +8.5% | 837,133 | +1.0% | 0.01% | 0.0% |
| Q3 2021 | $46,404,000 | -7.6% | 828,649 | +0.1% | 0.01% | -14.3% |
| Q2 2021 | $50,208,000 | -9.7% | 827,427 | +4.3% | 0.01% | -22.2% |
| Q1 2021 | $55,585,000 | +25.0% | 793,062 | +6.8% | 0.01% | +28.6% |
| Q4 2020 | $44,451,000 | +7.0% | 742,842 | +7.5% | 0.01% | -12.5% |
| Q3 2020 | $41,527,000 | +12.3% | 690,736 | -2.0% | 0.01% | 0.0% |
| Q2 2020 | $36,968,000 | +64.1% | 704,562 | +4.8% | 0.01% | +33.3% |
| Q1 2020 | $22,534,000 | -61.1% | 672,083 | -47.5% | 0.01% | 0.0% |
| Q4 2019 | $57,966,000 | +145.7% | 1,279,638 | +106.5% | 0.01% | 0.0% |
| Q3 2019 | $23,588,000 | -11.5% | 619,616 | +1.1% | 0.01% | 0.0% |
| Q2 2019 | $26,651,000 | +27.6% | 612,820 | +11.7% | 0.01% | +20.0% |
| Q1 2019 | $20,888,000 | -53.0% | 548,824 | -46.9% | 0.01% | -28.6% |
| Q4 2018 | $44,462,000 | +88.0% | 1,033,548 | +114.8% | 0.01% | 0.0% |
| Q3 2018 | $23,647,000 | +62.3% | 481,139 | +5.8% | 0.01% | +75.0% |
| Q2 2018 | $14,574,000 | +12.1% | 454,732 | +8.9% | 0.00% | 0.0% |
| Q1 2018 | $13,001,000 | -32.4% | 417,399 | -0.9% | 0.00% | -42.9% |
| Q4 2017 | $19,229,000 | +22.9% | 421,237 | +1.1% | 0.01% | +16.7% |
| Q3 2017 | $15,646,000 | -18.5% | 416,675 | +3.5% | 0.01% | -25.0% |
| Q2 2017 | $19,206,000 | +14.7% | 402,650 | +9.7% | 0.01% | +14.3% |
| Q1 2017 | $16,739,000 | +48.7% | 367,089 | +5.3% | 0.01% | +40.0% |
| Q4 2016 | $11,257,000 | +9.5% | 348,530 | +16.0% | 0.01% | 0.0% |
| Q3 2016 | $10,280,000 | +3.7% | 300,452 | +2.2% | 0.01% | 0.0% |
| Q2 2016 | $9,911,000 | -28.7% | 293,865 | +11.9% | 0.01% | -28.6% |
| Q1 2016 | $13,909,000 | -27.3% | 262,536 | +5.4% | 0.01% | -36.4% |
| Q4 2015 | $19,128,000 | +93.6% | 249,101 | +3.6% | 0.01% | +83.3% |
| Q3 2015 | $9,879,000 | -40.9% | 240,377 | +1.7% | 0.01% | -40.0% |
| Q2 2015 | $16,708,000 | -17.6% | 236,263 | +3.5% | 0.01% | -16.7% |
| Q1 2015 | $20,274,000 | +6.2% | 228,199 | +5.9% | 0.01% | +9.1% |
| Q4 2014 | $19,096,000 | -7.2% | 215,403 | +1.4% | 0.01% | -15.4% |
| Q3 2014 | $20,582,000 | +6.8% | 212,363 | +1.2% | 0.01% | +8.3% |
| Q2 2014 | $19,271,000 | +47.5% | 209,799 | +12.4% | 0.01% | +33.3% |
| Q1 2014 | $13,065,000 | +33.3% | 186,674 | +9.5% | 0.01% | +28.6% |
| Q4 2013 | $9,800,000 | +27.5% | 170,479 | +6.7% | 0.01% | +16.7% |
| Q3 2013 | $7,684,000 | +133.8% | 159,793 | +41.0% | 0.01% | +100.0% |
| Q2 2013 | $3,287,000 | – | 113,333 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |